Vir enters oncology collaboration with Gilead
Vir Biotechnology partners with Gilead Sciences to discover and develop novel dual-masked T-cell engagers for solid tumors, receiving an upfront payment of $90 million.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed